Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 2, 2024

https://www.globenewswire.com/news-release/2024/05/02/2874308/0/en/Aprea-Therapeutics-Announces-Appointment-of-Nadeem-Q-Mirza-M-D-M-P-H-as-Chief-Medical-Officer-and-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html

DOYLESTOWN, Pa., May 02, 2024 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq:APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced the appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer (CMO) of the Company, effective May 1, 2024. Dr. Mirza has been an integral part of the Company’s senior team as a consultant since February, 2023 and will now assume a more central role in leading the Company’s development of its expanding clinical pipeline.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.